1 / 16

PSI National Dialogue on Waste Pharmaceuticals

The goal of the Pharmaceuticals Dialogue is to reduce waste and develop a coordinated system for the safe management of pharmaceuticals. This dialogue involves research, stakeholder interviews, workgroups, and the involvement of government, waste industry, pharmacies, and healthcare groups. It also addresses disposal options, regulatory barriers, and the importance of source reduction. For more information, visit the PSI webpage.

raem
Download Presentation

PSI National Dialogue on Waste Pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PSI National Dialogue on WastePharmaceuticals Product Stewardship Forum June 2, 2009

  2. Goal of the Pharmaceuticals Dialogue • Reduce the amount of pharmaceuticals that become waste. • Develop and implement a nationally-coordinated system for the safe, practical, legal, and environmentally protective management of waste pharmaceuticals. • Focus: waste pharmaceuticals generated from households, or as household waste (including pets).

  3. Process • Research/stakeholder interviews • 2 meetings • 4 workgroups • Research • Source Reduction • Collection/disposal • Regulations

  4. Federal Government • U.S. Department of Transportation • U.S. Environmental Protection Agency • U.S. Food and Drug Administration • U.S. Postal Service • Office of National Drug Control Policy (observers) • Offices of Congressmen Inslee and Moran

  5. Pharmaceutical Companies/Waste Industry • AstraZeneca • BD Medical • GlaxoSmithKline • Generic Pharmaceutical Association • Hoffman-La Roche • Johnson & Johnson • King Pharmaceuticals ( and Alpharma) • Purdue Pharmaceuticals • Schering-Plough • Capital Returns, Inc. • Clean Harbors, LLC • Enserv West • EXP Pharmaceuticals • Heritage Environmental Services • Integrated Waste Control, LLC • PharmWaste Technologies • Sharps Compliance, Inc. • Stericycle • Veolia Environmental Services • Waste Management

  6. Pharmacies/Pharmacists/Healthcare Groups • American Pharmacists Association • Avalere Health, LLC • California Retailers Association • Healthcare Without Harm • Healthcare Distribution Management Association • Kaiser Permanente • Maryland Hospitals for a Healthy Environment • National Association of Chain Drug Stores • National Community Pharmacists Association • National Association of Consultant Pharmacists • National Association of Medical Device Reprocessors • PharmEcology Associates • Teleosis Institute

  7. Water, Environment & Public Health • Alliance for the Great Lakes • American Water Works Association • Association of State Drinking Water Administrators • Association of State and Interstate Water Pollution Control Administrators • California Product Stewardship Council & Northwest Product Stewardship Council • Clean Water Action • Earth 911 • Environmental Working Group • IL/IN Sea Grant • Natural Resources Defense Council • National Association of Clean Water Agencies • National Association of Drug Diversion Investigators • National Safety Council • New England Interstate Water Pollution Control Commission • Oregon Poison Control • Save the Bay • Washington Citizens for Resource Conservation • Women’s Health and Environment Network

  8. What is the size of the problem? Source Reduction The Problem Disposal Options for Waste Pharmaceuticals Household Trash Disposal Flushing (13 Substances) Take-backs Preferred Disposal Facilities Reduce Regulatory Barriers to Cut Cost, Ensure Safety, Enhance Environment

  9. Clear & Consistent Message

  10. Facilitating Cost-effective Take-back • Comments to DEA • Comments to EPA • UWR Change • Input on Inslee/Moran bill • Upcoming call to discuss next steps

  11. Trash vs. Take-back • Some ready to move, some want more information • Complex questions to answer: • What are people most likely to do? • Excretion v. disposal? • Impact on poisonings/diversion? • Ultimate disposal options • Preferred disposal for envt/safety • Capacity • Upcoming calls

  12. Source Reduction • Convene a summit to bring the “front end” and the “back end” of the problem together. • Potential strategies: • use samples differently • dispense smaller quantities • improve patient compliance • more accurate dosing • choose drugs according to ecotoxicity

  13. PSI Letters of Support • Maine • Oregon • Washington

  14. http://www.takebacknetwork.com

  15. For more information PSI webpage: http://www.productstewardship.us/pharmaceuticals Sierra Fletcher, Associate-Policy and Programs (617) 236-4886 Sierra@productstewardship.us

More Related